Plot No.367, Abhey Pur, Industrial Area Phase-1, Panchkula, Haryana 134109
Don't miss out on this limited-time offer to join our successful PCD Pharma network. Fill in your details below and our team will get in touch with you to discuss the best franchise opportunities tailored to your needs.
Glimepiride I.P. 2mg + Voglibose I.P. 0.3mg + Metformin HCL I.P. 500mg (S.R.) Bi-Layered Tablets
Therapeutic Category
Antidiabetic, Diabetic, Endocrinology
Dosage Form
Tablet
Packaging Type
Blister
Packaging
10*15
Price
₹193.5/-
High-resolution images and Product visuals
Product overview and usage information
Detailed information and research documents
Vogliviga GM2/0.3 Tablet combines Glimepiride 2mg, Voglibose 0.3mg, and Metformin 500mg (Sustained Release) in a bi-layered tablet designed for effective management of type 2 diabetes mellitus. Glimepiride stimulates insulin secretion to lower blood sugar levels, Voglibose delays carbohydrate absorption to reduce post-meal glucose spikes, and sustained-release Metformin improves insulin sensitivity while reducing glucose production in the liver. This multi-action formulation helps maintain balanced blood glucose levels throughout the day.
Common side effects may include gastrointestinal discomfort such as nausea, abdominal pain, bloating, and diarrhea. Hypoglycemia can occur, particularly if meals are missed or dosing is incorrect. Long-term use of Metformin may lead to vitamin B12 deficiency in some patients.
This tablet is indicated for the treatment of type 2 diabetes mellitus, especially in patients who require better control of both fasting and postprandial blood sugar levels.
Not suitable for patients with type 1 diabetes, diabetic ketoacidosis, or severe liver and kidney impairment. Alcohol consumption should be avoided. Regular monitoring of blood sugar is essential, and the medication should be taken as directed by a healthcare professional.
Store in a cool, dry place below 25°C, away from direct sunlight and moisture. Keep out of reach of children.
Composition : Metformin (500mg) SR + Voglibose (0.3mg) Tablet
Composition : Metformin (500mg) SR + Voglibose (0.2mg) Bilayered Smart Tablet
Composition : Glimepiride (2mg) + Metformin (500mg) SR + Voglibose (0.2mg) Bilayered Smart Tablet
Composition : Rosuvastatin 10 mg tablet
Composition : Rosuvastatin (20mg) tablet
Composition : Rosuvastatin 40 mg tablet
Composition : Rosuvastatin 5mg + fenofibrate 160 mg tablet
Composition : Rosuvastatin 20 mg + aspirin 75 mg tablet
Composition : Atorvastatin Calcium I.P. 10mg Tablets
Composition : Atorvastatin Calcium I.P. 20mg Tablets
This catalog is a digital representation of the Cafoli Lifecare portfolio and is intended for use by authorized pharmaceutical distributors and PCD franchise partners.
Vogliviga GM 2/0.3 Tablet has strong demand in the anti-diabetic and metabolic care segment, making it a valuable product for medical distributors, wholesalers, and pharma franchise partners focusing on diabetes management portfolios.
Medical distributors and agencies can benefit from consistent demand for management of Type 2 Diabetes Mellitus and blood sugar control. Glimepiride 2mg helps stimulate insulin release from the pancreas Voglibose 0.3mg helps reduce post-meal blood sugar spikes by delaying carbohydrate absorption Metformin HCL 500mg (S.R.) helps improve insulin sensitivity and reduce glucose production in the liver Together, this triple-combination bi-layered tablet provides comprehensive glycemic control, strengthening a reliable diabetic-care portfolio.
Yes, Cafoli LifeCare Pvt Ltd offers PCD pharma franchise opportunities for Vogliviga GM 2/0.3 Tablet with promotional support, monopoly rights, attractive packaging, and competitive pricing for distributors and wholesalers.
Wholesalers and medical agencies benefit from strong diabetologist and physician prescriptions, chronic long-term therapy demand, high market growth in diabetic medicines, reliable supply chain support, and good margins in anti-diabetic products.
Interested distributors, stockists, and wholesalers can contact Cafoli LifeCare Pvt Ltd to discuss pricing, monopoly territory rights, and distribution opportunities.